Cryopyrinopathies: update on pathogenesis and treatment.

Area of Science:

• Genetics
• Immunology
• Rheumatology

Background:

• Cryopyrinopathies encompass rare autoinflammatory syndromes including familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and chronic infantile neurologic cutaneous articular syndrome.
• These conditions were previously viewed as distinct but share clinical similarities and are now understood as subphenotypes of a disease continuum.
• The underlying genetic cause is mutations in the CIAS1 gene, now known as NLRP3, which encodes NALP3 (cryopyrin).

Purpose of the Study:

• To elucidate the genetic basis and disease continuum of cryopyrinopathies.
• To highlight the role of NALP3 (cryopyrin) in inflammation and interleukin-1beta processing.
• To discuss the translational impact of genetic findings on developing targeted therapies.

Main Methods:

• Genetic analysis identifying mutations in the CIAS1/NLRP3 gene across different cryopyrinopathy subtypes.
• Review of clinical presentations to establish a disease continuum.
• Evaluation of emerging biologic therapies targeting interleukin-1beta.

Main Results:

• Identical NLRP3 gene mutations are found in familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and chronic infantile neurologic cutaneous articular syndrome.
• NALP3 (cryopyrin) is identified as a key mediator in inflammation and interleukin-1beta processing.
• Biologic agents targeting interleukin-1beta demonstrate significant efficacy in treating these previously refractory inflammatory conditions.

Conclusions:

• Cryopyrinopathies represent a spectrum of disease driven by NLRP3 mutations, not distinct entities.
• Targeted therapies inhibiting interleukin-1beta offer effective treatment options.
• The development of these therapies exemplifies successful translation from basic science and human genetics to clinical practice.